Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;15(8):1008.
doi: 10.3390/genes15081008.

Prevalence of the FMR1 Gene Premutation in Young Women with a Diminished Ovarian Reserve Included in an IVF Program: Implications for Clinical Practice

Inés Agustí  1 , Marta Méndez  1 , Aina Borrás  1   2 , Anna Goday  1 , Marta Guimerà  1 , Sara Peralta  1 , Laura Ribera  1 , Laia Rodriguez-Revenga  3   4 , Dolors Manau  1   2
Affiliations

Prevalence of the FMR1 Gene Premutation in Young Women with a Diminished Ovarian Reserve Included in an IVF Program: Implications for Clinical Practice

Inés Agustí et al. Genes (Basel). .

Abstract

The relationship between premature ovarian insufficiency (FXPOI) and premutation in the FMR1 gene is well established. In recent years, though, a potential relationship between the latter and a low ovarian reserve has been suggested. To explore it, we conducted a retrospective study in an IVF program at a university tertiary referral center in Barcelona (Spain). Data were obtained retrospectively from a total of 385 women referred for FMR1 gene testing at our institution from January 2018 to December 2021. We compared the prevalence of FMR1 gene premutation between 93 of them, younger than 35 years, with a diminished ovarian reserve (DOR), characterized by levels of anti-Mullerian hormone < 1.1 ng/mL and antral follicle count < 5; and 132 egg donors screened by protocol that served as the controls. We found a higher prevalence of FMR1 premutation in the DOR group (seven patients (7.69%)) than in the control group (one patient (1.32%)), Fisher-exact test p-value = 0.012). We concluded that compared with the general population represented by young egg donors, the prevalence of FMR1 gene premutation is higher in young patients with a diminished ovarian reserve. Although these findings warrant further prospective validation in a larger cohort of patients within DOR, they suggest that, in clinical practice, FMR1 premutation should be determined in infertile young patients with DOR in order to give them adequate genetic counselling.

Keywords: FMR1 premutation; POSEIDON 3; premature ovarian failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Consort diagram of the study. DOR: diminished ovarian reserve.
Figure 2
Figure 2
Fisher’s exact test p = 0.012. DOR: diminished ovarian reserve.
See this image and copyright information in PMC

References

    1. Turner G., Webb T., Wake S., Robinson H. Prevalence of fragile X syndrome. Am. J. Med. Genet. 1996;64:196–197. doi: 10.1002/(SICI)1096-8628(19960712)64:1<196::AID-AJMG35>3.0.CO;2-G. - DOI - PubMed
    1. Fu Y.H., Kuhl D.P., Pizzuti A., Pieretti M., Sutcliffe J.S., Richards S., Verkerk A.J., Holden J.J., Fenwick R.G., Jr., Warren S.T., et al. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell. 1991;67:1047–1058. doi: 10.1016/0092-8674(91)90283-5. - DOI - PubMed
    1. Cronister A., Schreiner R., Wittenberger M., Amiri K., Harris K., Hagerman R.J. Heterozygous fragile X female: Historical, physical, cognitive, and cytogenetic features. Am. J. Med. Genet. 1991;38:269–274. doi: 10.1002/ajmg.1320380221. - DOI - PubMed
    1. Hagerman R.J., Amiri K., Cronister A. Fragile X checklist. Am. J. Med. Genet. 1991;38:283–287. doi: 10.1002/ajmg.1320380223. - DOI - PubMed
    1. Huang J., Zhang W., Liu Y., Liu Y., Wang J., Jiang H. Association between the FMR1 CGG repeat lengths and the severity of idiopathic primary ovarian insufficiency: A meta analysis. Artif. Cells Nanomed. Biotechnol. 2019;47:3116–3122. doi: 10.1080/21691401.2019.1645153. - DOI - PubMed

Substances

LinkOut - more resources